Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Le Chesnay-Rocquencourt – page 111

3 344 clinical trials in Le Chesnay-Rocquencourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Chesnay-Rocquencourt at a glance
3 344
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 344 trials in Le Chesnay-Rocquencourt

Open in trial search

Arthralgia

Not yet recruiting

Efficacy of embolization using ethyl esters of iodised fatty acids and ioversol in patients with painful joints (knee osteoarthritis, frozen shoulder, elbow tendinopathy)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ioversol
  • Sponsor:Assistance Publique Hopitaux De Paris

Idiopathic pulmonary fibrosis

Not yet recruiting

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.U.

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Colitis ulcerative

Not yet recruiting

Evaluation of Upadacitinib Re‑induction in Patients with Ulcerative Colitis Who Have Lost Response to a 30 mg Maintenance Dose

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:i-GETAID

Lichen planopilaris

Not yet recruiting

Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Priovant Therapeutics Inc.

Myopathy

Not yet recruiting

Long‑term safety and tolerability of ASP2957 in boys with X‑linked myotubular myopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:ASP2957
  • Sponsor:Astellas Gene Therapies Inc.

Retinoblastoma

Not yet recruiting

Carboplatin with drug combination for children with unilateral retinoblastoma undergoing enucleation: study of tumor biomarkers and relapse risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Transitional cell carcinoma+1

Not yet recruiting

Phase 3 Study of trastuzumab brengitecan versus platinum‑based chemotherapy in adults with HER2‑positive metastatic urothelial cancer after anti‑PD‑(L)1 therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Systimmune Inc.

Facioscapulohumeral muscular dystrophy

Not yet recruiting

Phase 2 Study of Apitegromab in Patients with Facioscapulohumeral Muscular Dystrophy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

Cutaneous sarcoidosis

Not yet recruiting

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Priovant Therapeutics Inc.

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Reducing abemaciclib, palbociclib and ribociclib after complete response in HER2‑negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Le Chesnay-Rocquencourt

What the registry says about research in the country

01 Cardiology & Respiratory Medicine

Clinical trials focusing on acute myocardial infarction pain management and innovative treatments for severe asthma. Research includes evaluation of novel pain-relief methods and assessment of treatment discontinuation strategies.

  • Pain management in heart attacks
  • Asthma treatment optimization
  • Heart failure management

Studies also examine beta-blocker discontinuation in patients with recovered heart function.

02 Oncology & Hematology

Extensive research in blood cancers, including multiple myeloma, acute myeloid leukemia, and various lymphomas. Studies evaluate novel drug combinations and treatment strategies.

  • Blood cancer therapies
  • Leukemia treatments
  • Breast cancer management

Investigations include targeted therapies and personalized treatment approaches for various cancer types.

03 Pediatric & Infectious Diseases

Research focusing on respiratory syncytial virus (RSV) prevention in infants and children. Studies evaluate new protective treatments and their safety profiles.

  • RSV prevention
  • Infant protection studies
  • Immunotherapy research

Trials include assessment of novel medications for preventing severe respiratory infections in vulnerable populations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.